Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
grade C 17.65 1.96% 0.34
GLYC closed up 1.96 percent on Friday, April 20, 2018, on 39 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical GLYC trend table...

Date Alert Name Type % Chg
Apr 20 NR7 Range Contraction 0.00%
Apr 20 BB Squeeze Ended Range Expansion 0.00%
Apr 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.96%
Apr 19 Bollinger Band Squeeze Range Contraction 1.96%
Apr 19 BB Squeeze Started Range Contraction 1.96%
Apr 19 BB Squeeze + Upper Band Touch Range Contraction 1.96%
Apr 19 Outside Day Range Expansion 1.96%
Apr 19 Upper Bollinger Band Touch Strength 1.96%
Apr 18 Doji - Bearish? Reversal -2.11%
Apr 18 BB Squeeze Ended Range Expansion -2.11%

Older signals for GLYC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Is GLYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.05
52 Week Low 3.82
Average Volume 933,957
200-Day Moving Average 15.3646
50-Day Moving Average 19.4454
20-Day Moving Average 16.7825
10-Day Moving Average 17.295
Average True Range 1.0928
ADX 18.63
+DI 20.92
-DI 20.0
Chandelier Exit (Long, 3 ATRs ) 15.2016
Chandelier Exit (Short, 3 ATRs ) 18.6984
Upper Bollinger Band 18.3081
Lower Bollinger Band 15.2569
Percent B (%b) 0.78
BandWidth 18.180843
MACD Line -0.2988
MACD Signal Line -0.6122
MACD Histogram 0.3133
Fundamentals Value
Market Cap 577.56 Million
Num Shares 32.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -13.17
Price-to-Sales 18873.21
Price-to-Book 3.02
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.48
Resistance 3 (R3) 18.39 18.04 18.34
Resistance 2 (R2) 18.04 17.83 18.08 18.29
Resistance 1 (R1) 17.84 17.70 17.94 17.93 18.25
Pivot Point 17.49 17.49 17.54 17.53 17.49
Support 1 (S1) 17.29 17.28 17.39 17.38 17.05
Support 2 (S2) 16.94 17.15 16.98 17.01
Support 3 (S3) 16.74 16.94 16.96
Support 4 (S4) 16.83